Company intelligence / Profile preview

Cuorips

Ownership: Private
Employees: ~59
Development stage: Other

Overview

Cuorips has developed an allogeneic iPS cell-derived cardiomyocyte sheet for severe heart failure. In a clinical trial with eight patients, the treatment was shown to be safe and effective in improving symptoms. The company applied for Japanese regulatory approval in April 2025, marking the world’s first such application for an iPS-based regenerative medical product. No major side effects were observed during trials.

Therapeutic areas: Cardiovascular
Modalities: Induced pluripotent stem cell derived therapyCell therapyRegenerative medicine product
Industry: Biotech

Drug pipeline

3 assets

Human (allogeneic) iPS cell derived-cardiomyocyte sheet

2 more assets in the full pipeline.

Request access →

Partnerships

Daiichi Sankyo – option right for worldwide commercialization of the technologyOsaka University – foundational research/collaborationStanford University Department of Cardiothoracic Surgery – joint research agreement

Beyond the preview

Go deeper on Cuorips.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cuorips.

Explore the full profile